Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?

Camille Danne; Harry Sokol

doi:10.1016/j.xcrm.2021.100328

Butyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?

Cell Rep Med. 2021 Jul 7;2(7):100328. doi: 10.1016/j.xcrm.2021.100328. eCollection 2021 Jul 20.

Authors

Camille Danne^{1

2}, Harry Sokol^{1

2

3}

Affiliations

¹ INRA, UMR1319 Micalis & AgroParisTech, Jouy en Josas, France.
² Paris Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.
³ Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology department, F-75012 Paris, France.

Abstract

The intestinal microbiota is a new promising avenue in cancer immunotherapy, but mechanisms remain elusive. He et al. demonstrate that butyrate, a bacterial metabolite, enhances the CD8+ T cell response and improve chemotherapy efficacy through ID2-dependent IL-12 signaling.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Butyrates
CD8-Positive T-Lymphocytes
Gastrointestinal Microbiome*
Humans
Microbiota*
Neoplasms* / drug therapy

Substances

Butyrates